CMP as on 22-Jan-21 15:58₹ 56.45
Turnover (lac)₹ 531
Prev. Close₹ 56.85
Day's Vol (shares)₹ 9,41,403
Day's Range (₹)
CMP as on22-Jan-21 15:34₹ 56.45
Turnover (lac)₹ 37
Prev. Close₹ 56.70
Day's Vol (shares)₹ 1,43,160
15:57 IST, Oct 05
The tablets are indicated as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
14:28 IST, Aug 04
Consolidated revenue increased by 34% to Rs331.3cr in the quarter under review, as against Rs247.2cr a year ago same period.
14:01 IST, Jun 08
Metformin Extended Release Tablets USP500 mg is indicated as an adjunct to diet and exercise to improve blood glucose control in adults
14:01 IST, Apr 23
India Ratings & Research (Fitch Group) has revised Marksans outlook to Positive from Stable.
12:40 IST, Feb 11
The company received EIR from the USFDA in respect of inspection of company's manufacturing facility Time-Cap Laboratories Inc. located
16:05 IST, Jun 06
The company said that it received the Establishment Inspection Report from the USFDA in respect of inspection of the company's Goa faci
14:57 IST, Mar 07
The inspection of the facility took place between February 25 to March 6, 2019.
- 12:58 IST, Nov 13
14:28 IST, Oct 09
The stock is currently trading at Rs 50.8, up by Rs 3 or 6.28% from its previous closing of Rs 47.8 on the BSE.
- 14:27 IST, Aug 11